Trident Lifeline Ltd. Share Price

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) and in accordance with the applicable provisions of the Companies Act, 2013 and rules framed thereunder, Trident Lifeline has informed that it enclosed the Notice of Postal Ballot and Remote e-Voting, together with Explanatory Statement thereto, seeking approval of members of the Company by passing Special Resolutions through Postal Ballot process by way of Remote e-Voting only. The aforementioned Notice is being sent through electronic mode today, June 15, 2026, to all the Members, who have registered their email addresses with the Company/Depositories/Registrar and Transfer Agents of the Company - MUFG Intime India (formerly Link Intime India) and whose names appear in the Register of Members as on Friday, June 05, 2026 being the cut-off date. The same is also available on the website of the Company at www.tridentlifeline.com. The Remote e-Voting period will commence on 09:00 am (IST) on Tuesday, June 16, 2026 and ends at 05:00 pm (IST) on Wednesday, July 15, 2026, and the result thereof will be declared on or before Friday, July 17, 2026. 

The above information is a part of company’s filings submitted to BSE. 

Trident Lifeline has informed that it enclosed disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shikha Bafna.

The above information is a part of company’s filings submitted to BSE. 

Sandu Pharmaceuticals has informed that a Meeting of the Board of Directors of the Company will be held on Saturday, the 11th day of July 2026 at 04:00 pm at the Corporate Office of the Company at Sandu Pharmaceuticals, Sandu Nagar, D K Sandu Marg, Chembur, Mumbai 400071 to consider the following 1. To place on record the demise of Shri Umesh B. Sandu (DIN:01132141), Managing Director of the Company, on 19th June, 2026, and to record the Board's appreciation for his invaluable contribution to the Company. 2. To consider and approve the appointment of a Managing Director of the Company pursuant to the demise of the erstwhile Managing Director, Late Shri Umesh B. Sandu, subject to the approval of the shareholders of the Company and such other statutory and regulatory approvals as may be required. 3. To consider and approve the reconstitution of the Committees of the Board. 4. To consider and approve the appointment of an Additional Director in the capacity of an Independent Director (Non-Executive) on the Board of the Company, subject to the approval of the shareholders of the Company and such other statutory and regulatory approvals, if any, as may be required. This notice is being submitted pursuant to Regulation 29 of the Securities & Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulation 2015. In Compliance with the Company’s Code of Conduct for prevention of Insider Trading devised as per the SEBI (Prohibition of Insider Trading) the company has informed that the trading window for dealing in the Securities of the Company has been closed for the Company’s Directors/Officer and designated employees of the Company from the opening of Trading hours on Wednesday, 1st day of July 2026 till 48 hours after announcement of financial results to public for the Quarter ended 30th June 2026 in compliances with the code of conduct for prevention of Insider Trading Regulation 2015. 

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharmaceuticals has informed about the launch of Olanzapine for Injection, 10 mg/vial, Single‐Dose Vial. Glenmark’s Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa® IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253]. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.